Previous evidence indicates that Toll-like receptor 4 contributes to the development of paclitaxel resistance in advanced breast cancer cells by increasing the expression of pro-inflammatory cytokines such as IL-6 and IL-8, as well as the anti-apoptotic protein XIAP (37). Here, IL6 is linked to breast carcinoma.